Skip to main content
Premium Trial:

Request an Annual Quote

Revenues and Earnings Up for Qiagen in Q1

NEW YORK, May 4 (GenomeWeb News) - Qiagen yesterday reported increased revenues and slightly higher earnings for the first quarter of 2004.


The company booked $96.1 million in revenues, up from $79.6 million during the same quarter last year. Almost 80 percent of revenues resulted from consumables, and about 10 percent each from instruments and oligos.


Research and development costs climbed to $9.4 million, from $7.5 million during the same quarter in 2003.


Qiagen's net income increased slightly to $11.4 million, or $.08 per share, from $11 million, or $.08 per share, during the year-ago period.


As of March 31, Qiagen had $108.8 million in cash and cash equivalents.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.